SOLID DISPERSION OF NEBIVOLOL HYDROCHLORIDE IMPREGNATED BUCCAL PATCH: FORMULATION AND CHARACTERIZATION

  • sneh priya Nitte University

Abstract

Objective: The objective of the present investigation was to design and characterize a mucoadhesive buccal patch of Nebivolol hydrochloride in order to administer a small dose of the drug to treat hypertension effectively and thereby avoiding disadvantages such as patient noncompliance and low bioavailability.


Method: The buccal patches were prepared by solvent casting method. The polymers used for the formulation of patches were HPMC K 15 M, PVP K 30, and propylene glycol was used as plasticizer and ethanol as the solvent. The drug-polymer compatibility studied was conducted by FTIR.


Results: All the developed Patches had good transparency and stability. All formulated patches showed pH in the range of 6.49 to 7.22, drug content was found to be more than 90%. The folding endurance value showed that the patches are flexible and non-brittle. The in-vitro residence time was found to more than 30 min. Thickness, % moisture absorption, and % moisture loss values were in a normal range. The drug release study was conducted for 8 h and it was found drug release was decreased with the increase in polymer concentration. The in vitro release profiles of the drug from all the formulations appeared to follow Korsmeyer Peppa’s exponential model, and release exponent (n) was found to be more than 0.45 so that the release can be characterized by Non–Fickian (anomalous) diffusion.


Conclusion: From the results, it was concluded that drug released from formulated buccal patches follows a sustained release pattern, Hence can be used for the treatment of a hypertensive patient.

Keywords: Nebivolol hydrochloride (NBH), Mucoadhesive buccal patch, HPMC K 15 M

References

1. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson J.G, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J hypertens. 2014;32(1):3-15.
2. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J hypertens. 2004;22(1):11-9.
3. Gavhane YN, Yadav AV. Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012;20(4):331-44.
4. Harris D, Robinson JR. Drug Delivery via the mucous membrane of the oral cavity. J Pharm Sci 1992; 81:1-10
5. Tarun P, Kumar V, Kumar A. Drug delivery via the buccal patch- a novel approach. Indo American J Pharm Res. 2013;3(5):3466-83.
6. Veverka A, Nuzum DS, Jolly JL. et al. Nebivolol: A third generation ?-adrenergic blocker. Ann Pharmacother. 2006;40:1353- 60
7. Shah I, Bhatt S, Yadav A. Enhancement of Solubility and Dissolution of Nebivolol by Solid Dispersion Technique. Int J Pharm Pharm Sci. 2014;6(7):566-71.
8. Shah H, Shah V, Bhutani S, Parikh D, Mehta T. Dissolution improvement of nebivolol hydrochloride using solid dispersion adsorbate technique. Asian J Pharm 2015;9:49-55
9. Hirlekar RS. Design of buccal drug delivery system for a poorly soluble drug. Asian J Pharm Clinical Res. 2009;2(3):49-53
10. Periolia L, Ambrogia V, Angelicia F, Riccia M,Giovagnolia S, Capuccellab M, Rossi C. Development of mucoadhesive patches for buccal administration of ibuprofen. J Cont Rel. 2004;9(3):73-82.
11. Priya S, Rathnanand M, Udupa N, Ongole R, Sumanth KN, Joshi U. Preparation and Evaluation of Buccal Mucoadhesive Patch of Betamethasone Sodium Phosphate for the Treatment of Oral Submucous Fibrosis. J. Chem. Pharm. Res. 2011; 3(6):56-65
12. Patel VM, Prajapati BG, Patel MM. Design and in vitro characterization of eudragit containing mucoadhesive buccal patches. Int J Pharm Tech Res. 2009; 1(3): 783-9.
13. Averineni RK, Sunderajan SG, Mutalik S, Nayak U, Shavi G, Armugam K, Udupa N. Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. Pharm Dev Technol. 2009; 14(2): 199–207.
14. Deshpande PB, Dandagi P, Udupa N, Shavi VG, Jain SS, Vasanth SG. Controlled release polymeric ocular delivery of Acyclovir. Pharm Dev Technol. 2009; 15(4):369-78
15. Thakur P, Ratnaparkhi MP. Formulation and Evaluation of Mouth Dissolving Film of Felodipine. 2014; 7(10) : 1145-1149
16. Wani MS, Dehghan MH, Mahendrakumar C, Polshettiwar SA, Yadav VB. Design and evaluation of Terbutaline Sulphate buccal patch. Research Journal of Pharmacy and Technology. 2009; 2(1): 86-90
17. Singhvi G, Singh M. Review: In Vitro drug release charecterization models. International Journal of Pharmaceutical Studies and Research. 2011;2(1):77-84
18. Moffat AC, Osselton MD, Brain W. Clarke's Analysis of Drugs and Poisons overview, 3rd Edition. Pharmaceutical Press, Londom. 2009.
19. Gupta JRD, Irchhiaya R, Garud N, Tripathi P, Dubey, P, Patel JR. Formulation and evaluation of matrix type transdermal patches of glibenclamid, Int. J.Pharm. Sci, Drug Res. 2009;1(1): 46-50.
20. Gawai N, Zaheer Z. formulation and development of mucoadhesive sustained release buccal tablets and patches of 5-fluorouracil using different polymers. Asian J Pharm Clin Res. 2018;11(5):174-85.
21. Patel RS, Poddar SS. Development and Characterization of Mucoadhesive Buccal Patches of Salbutamol Sulphate. Current Drug Delivery. 2009; 6: 140-144.
22. Ashutosh R, Prabhakara P, Akhilesh D. Design and evaluation of buccal patches containing combination of hydrochlorothiazide and atenolol. Int J App Pharm. 2018;10(2):105-12.
Statistics
2 Views | Downloads
Citations
How to Cite
priya, sneh. (2021). SOLID DISPERSION OF NEBIVOLOL HYDROCHLORIDE IMPREGNATED BUCCAL PATCH: FORMULATION AND CHARACTERIZATION. International Journal of Applied Pharmaceutics, 13(3). https://doi.org/10.22159/ijap.2021v13i3.40851
Section
Original Article(s)